BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2018 10:20:22 AM | Browse: 1096 | Download: 1652
 |
Received |
|
2018-07-24 02:37 |
|
Peer-Review Started |
|
2018-07-24 07:46 |
|
To Make the First Decision |
|
2018-08-30 02:03 |
|
Return for Revision |
|
2018-08-30 02:28 |
|
Revised |
|
2018-09-05 18:03 |
|
Second Decision |
|
2018-10-11 09:30 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-10-11 18:39 |
|
Articles in Press |
|
2018-10-11 18:39 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2018-10-15 03:56 |
|
Typeset the Manuscript |
|
2018-10-30 08:13 |
|
Publish the Manuscript Online |
|
2018-11-06 10:20 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Case Report |
| Article Title |
Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jian-Chun Lu, Long-Gen Liu, Lin Lin, Shu-Qin Zheng and Yuan Xue |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Chinese Foundation for Hepatitis Prevention and Control- WBE Liver Fibrosis Foundation |
WBE20161013 |
| the Science and Technology project of Changzhou |
CJ20160024, CJ20179030 |
|
| Corresponding Author |
Yuan Xue, PhD, Chief Doctor, Department of Liver Diseases, the Third People’s Hospital of Changzhou, No. 300 Lanling North Road, Changzhou 213000, Jiangsu Province, China. xueyuan80908@163.com |
| Key Words |
Tenofovir alafenamide; Disoproxil fumarate; Hepatocellular carcinoma; Hepatitis B virus; Mutation |
| Core Tip |
Tenofovir alafenamide rescues multidrug resistance and renal dysfunction in an old patient but does not eliminate the risk of hepatocellular carcinoma (HCC) development. Despite controlling the viral load, risk of HCC exists and should be monitored in cirrhotic patients. |
| Publish Date |
2018-11-06 10:20 |
| Citation |
Lu JC, Liu LG, Lin L, Zheng SQ, Xue Y. Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature. World J Clin Cases 2018; 6(13): 671-674 |
| URL |
http://www.wjgnet.com/2307-8960/full/v6/i13/671.htm |
| DOI |
http://dx.doi.org/10.12998/wjcc.v6.i13.671 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
